Czy leki beta-adrenolityczne zapobiegają progresji miażdżycy? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2008
Słowa kluczowe:
leki β-adrenolityczne, zapobieganie, progresja miażdżycy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Miażdżyca jest przyczyną większości chorób układu krążenia. Obecnie nie posiadamy w pełni skutecznego środka, który potrafiłby spowolnić i/lub zahamować ten proces. Autorzy artykułu na podstawie aktualnego stanu wiedzy podjęli próbę umieszczenia beta-adrenolityków w grupie leków przeciwmiażdżycowych.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kuch , M., Światowiec , A., & Braksator , W. (2008). Czy leki beta-adrenolityczne zapobiegają progresji miażdżycy? . Kardiologia W Praktyce, 2(1), 30-37. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1696
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. De Lorgeril M., Salen P., Martin J.L. et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999, 99: 779-785.
2. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N.Engl.J.Med.1998, 339: 489-497.
3. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004, 25: 1341-62.
4. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002, 106: 394-398.
5. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981, 304: 801-807.
6. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981, 2: 823-827.
7. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982, 247: 1707-1714.
8. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985, 6: 199-226.
9. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction. Lancet 1986, 2: 57-66.
10. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991, 83: 422-437.
11. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J.Hypertens. 1993, 11(supl.4): S61-S73.
12. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 26: 1730-1737.
13. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomized trials in post-myocardial infarction patients. Eur. Heart J. 1988, 9: 8-16.
14. Yusuf S., Wittes J., Friedman L.: Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factors modification. JAMA 1988, 260: 2259-2263.
15. Bertrand M.E., Simoons M.L., Fox K.A. et al., Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST- segment elevation. Eur. Heart J. 2002, 23: 1809-1840.
16. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine, sixth edition. Braunwald E., Zippes D.P., Libby P. (red.). W.B. Saunders Company, Philadelphia 2001: 562-599.
17. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic Cardiol. 2002, 5: 215-223.
18. Tamargo J.L., Delpon E.: Optimisation of β-blockers pharmacology. J. Cardiovasc. Pharmacol. 1990, 16(supl.5): S8-S10.
19. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998, 339: 1759-1765.
20. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005, 1048: 98-107.
21. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001, 104: 1477-82.
22. Levy R.L., White P.D., Stroud W.D. et al.: Transient tachycardia: prognostic significance alone and in association with hypertension. J. Am. Med. Assoc.1945, 129: 585-588.
23. Jouven X., Desnos M., Guerot C., Ducimetiere P.: Predicting sudden death in population: the Paris Prospective Study I. Circulation 1999, 99: 1978-1983.
24. Greenland P., Daviglus M.L., Dyer A.R. et al.: Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. Am. J. Epidemiol. 1999, 149: 853-862.
25. Palatini P., Casiglia S., Julius S., Pessina A.C.: Heart rate, a risk factor for cardiovascular mortality in elderly men. Arch. Int. Med. 1999, 159: 585-592.
26. Kaplan J.R., Manuck S.B.: Antiatherogenic effects of beta-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations. Am. Heart J.1994, 128: 1316-28.
27. ESC Committee for Practice Guidelines: Guidelines on the management of stable angina pectoris. Executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal 2006, 27: 1341-1381.
28. Pasterkamp G., Falk E., Woltman H., Borst C.: Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making? J. Am. Coll. Cardiol. 2000, 36: 13-21.
29. Iglesias del Sol A., Bots M.L., Grobbee D.E. et al.: Carotid intima – media thickness at different sites: relation to incident myocardial infarction. The Rotterdam Study. Eur. Heart J. 2002, 23: 934-940.
30. Drechsler D., Kornacewicz-Jach Z.: Assessment of carotid arteries and pulse wave velocity in patients with three-vessel coronary artery disease. Kardiol. Pol. 2002, 57: 193-197.
31. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001, 103: 1721-1726.
32. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002, 33: 572-577.
33. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007, 147: 10-18.
34. Dunn C.J., Lea A.P., Wagstaff H.: Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997, 54: 161-185.
35. Ohtsuka T., Hamada M., Saeki H. et al.: Serum levels of matrix metalloproteinases and tumor necrosis factor in patients with idiopathic dilated cardiomyopathy and effects of carvedilol on these levels. Am. J. Cardiol. 2002, 91: 1024-1027.
36. Rossig L., Haendeler J., Mallat Z. et al.: Congestive heart failure induces cell apoptosis: protective role of carvedilol. JACC 2000, 36: 2081-2089.
37. Gage J.R., Fonarow G., Hamilton M. et al.: Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004, 11: 173-80.
38. Mayer B., Holmer S.R., Hengstenberg C. et al.: Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int. J. Cardiol. 2005, 103: 182-186.
39. Matsumura T., Tsushima K., Ohtaki E. et al.: Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J. Cardiol. 2002, 39: 253-257.
40. Tsutamoto T., Wada A., Matsumoto T. et al.: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001, 37: 2086-92.
41. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004, 286: H83-H90.
42. Prabhu S.D., Chandrasekar B., Murray D.R. et al.: Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000, 101: 2072-9. [Errata w: Circulation 2000, 102: 141].
43. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001, 38: 922-929.
44. Vyssoulis G.P., Marinakis A.G., Aznaouridis K.A. et al.: The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am. J. Hypertens. 2004, 17: 582-9.
45. Mallamaci F., Tripepi G., Maas R. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2004, 15: 435-441.
46. Feuerstein G.Z., Ruffolo R.R. Jr.: Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur. Heart J. 1996, 17(supl. B): 24-9.
47. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002, 53: 615-624.
48. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23: 615-621.
49. Ignarro L.J.: Experimental evidences of nitric oxide-dependent vasodilatatory activity of nebivolol, a third generation beta-blocker. Blood Pressure 2004, 13(S1): 3-17.
50. Cominacini L., Pasini A.F., Garbin U. et al.: Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. JACC 2003, 42: 1838-1844.
51. Arosio E., De Marchi S., Prior M. et al.: Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J. Hypertens. 2002, 30: 1793-1797.
52. Vittorio T.J., Lang C.C., Katz S.D. et al.: Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. Circulation 2003, 107: 290-293.
53. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000, 36: 3401-3403.
54. Kukin M.L., Kalman J., Charney R.H. et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99: 2645-51.
55. Nakamura K., Kusano K., Nakamura Y. et al.: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 105: 2867-71.
56. Lahiri A.: Neurohormonal mechanisms in congestive heart failure and the role of drugs with multiple actions: a review of carvedilol. Am. J. Therap. 1996, 3: 237-247.
57. Feuerstein G.Z., Yue T.L.: A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994, 48: 385-391.
58. Lopez B.L., Christopher T.A., Yue T.L. et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995, 51: 165-73.
59. De Grott A.A., Mathy M.J., van Zwieten P.A. et al.: Antioxidant activity of nebivolol in the rat aorta. J. Cardiovasc. Pharmacol. 2004, 43: 148-153.
60. Jacob S., Rett K., Henriksen E.J.: Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents. Am. J. Hypertens. 1998, 11: 1258-1265.
61. Van Os J.S., van Brummelen P., Woittiez A.J.J.: Betaxolol in obese hypertensive patients. Long term effects on blood pressure and serum lipids. Neth. J. Med. 1992, 40: 227-231.
62. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997, 314: 1512-1515.
63. He J., Ogden L.G., Bazzano L.A. et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiology follow-up study. Arch. Int. Med. 2001, 161: 996-1002.
64. Viscoli C.M., Horowitz R.I., Singer B.H.: Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann. Intern. Med. 1993, 118:99-105.
65. Pedersen T.R.: Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N. Engl. J. Med. 1985, 313: 1055-1058.
66. The Capricorn Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2002, 357: 1385-1390.
67. Aronow W.S., Ahn C., Kronzon I.: Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am. J. Cardiol. 2001, 88: 1298-1300.
68. Vantrimpont P., Rouleau J.L., Wun C.C. et al.: Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J. Am. Coll. Cardiol. 1997, 29: 229-236.
69. Swedberg K., Cleland J., Dargie H. et al, The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005, 26: 1115-1140.
70. Komajda M., Lutiger B., Madeira H. et al.: Tolerability of carvedilol and ACE-Inhibition in mild to heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN) Eur. J. Heart Fail. 2004, 6: 467-475.
71. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991, 325: 293-302.
72. Pfeffer M.A., Braunwald E., Moye L.A. et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992, 327: 669-77.
73. MERIT – HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomised Interventional Trial in Congestive Heart Failure (Merit–HF). Lancet 1999, 353: 2001-17.
74. CIBIS II Investigators and Committees: the Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet 1999, 353: 9-13.
75. Packer M., Coats A., Fowler M.B. et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001, 344: 1651-1658.
76. CIBIS investigators and committees: A randomized trial of betablockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994, 90: 1765-1773.
77. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112: 154-235.
78. Willenheimer R., van Veldhuisen D.J., Silke B. et al., CIBIS III Investigators: Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005, 112: 2426-2435.
79. Packer M., Bristow M.R., Cohn J.N. et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996, 334: 1349-1355.
80. The RESOLVD Investigators: Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation 2000, 101: 378-384.
81. Doughty R.N., Whalley G.A., Gamble G. et al., on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol. 1997, 29: 1060-1066.
82. Flather M.D., Shibata M.C., Coats A.J.S et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005, 26: 215-225.
2. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N.Engl.J.Med.1998, 339: 489-497.
3. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004, 25: 1341-62.
4. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002, 106: 394-398.
5. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981, 304: 801-807.
6. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981, 2: 823-827.
7. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982, 247: 1707-1714.
8. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985, 6: 199-226.
9. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction. Lancet 1986, 2: 57-66.
10. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991, 83: 422-437.
11. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J.Hypertens. 1993, 11(supl.4): S61-S73.
12. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 26: 1730-1737.
13. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomized trials in post-myocardial infarction patients. Eur. Heart J. 1988, 9: 8-16.
14. Yusuf S., Wittes J., Friedman L.: Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factors modification. JAMA 1988, 260: 2259-2263.
15. Bertrand M.E., Simoons M.L., Fox K.A. et al., Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST- segment elevation. Eur. Heart J. 2002, 23: 1809-1840.
16. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine, sixth edition. Braunwald E., Zippes D.P., Libby P. (red.). W.B. Saunders Company, Philadelphia 2001: 562-599.
17. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic Cardiol. 2002, 5: 215-223.
18. Tamargo J.L., Delpon E.: Optimisation of β-blockers pharmacology. J. Cardiovasc. Pharmacol. 1990, 16(supl.5): S8-S10.
19. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998, 339: 1759-1765.
20. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005, 1048: 98-107.
21. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001, 104: 1477-82.
22. Levy R.L., White P.D., Stroud W.D. et al.: Transient tachycardia: prognostic significance alone and in association with hypertension. J. Am. Med. Assoc.1945, 129: 585-588.
23. Jouven X., Desnos M., Guerot C., Ducimetiere P.: Predicting sudden death in population: the Paris Prospective Study I. Circulation 1999, 99: 1978-1983.
24. Greenland P., Daviglus M.L., Dyer A.R. et al.: Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. Am. J. Epidemiol. 1999, 149: 853-862.
25. Palatini P., Casiglia S., Julius S., Pessina A.C.: Heart rate, a risk factor for cardiovascular mortality in elderly men. Arch. Int. Med. 1999, 159: 585-592.
26. Kaplan J.R., Manuck S.B.: Antiatherogenic effects of beta-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations. Am. Heart J.1994, 128: 1316-28.
27. ESC Committee for Practice Guidelines: Guidelines on the management of stable angina pectoris. Executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal 2006, 27: 1341-1381.
28. Pasterkamp G., Falk E., Woltman H., Borst C.: Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making? J. Am. Coll. Cardiol. 2000, 36: 13-21.
29. Iglesias del Sol A., Bots M.L., Grobbee D.E. et al.: Carotid intima – media thickness at different sites: relation to incident myocardial infarction. The Rotterdam Study. Eur. Heart J. 2002, 23: 934-940.
30. Drechsler D., Kornacewicz-Jach Z.: Assessment of carotid arteries and pulse wave velocity in patients with three-vessel coronary artery disease. Kardiol. Pol. 2002, 57: 193-197.
31. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001, 103: 1721-1726.
32. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002, 33: 572-577.
33. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007, 147: 10-18.
34. Dunn C.J., Lea A.P., Wagstaff H.: Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997, 54: 161-185.
35. Ohtsuka T., Hamada M., Saeki H. et al.: Serum levels of matrix metalloproteinases and tumor necrosis factor in patients with idiopathic dilated cardiomyopathy and effects of carvedilol on these levels. Am. J. Cardiol. 2002, 91: 1024-1027.
36. Rossig L., Haendeler J., Mallat Z. et al.: Congestive heart failure induces cell apoptosis: protective role of carvedilol. JACC 2000, 36: 2081-2089.
37. Gage J.R., Fonarow G., Hamilton M. et al.: Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004, 11: 173-80.
38. Mayer B., Holmer S.R., Hengstenberg C. et al.: Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int. J. Cardiol. 2005, 103: 182-186.
39. Matsumura T., Tsushima K., Ohtaki E. et al.: Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J. Cardiol. 2002, 39: 253-257.
40. Tsutamoto T., Wada A., Matsumoto T. et al.: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001, 37: 2086-92.
41. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004, 286: H83-H90.
42. Prabhu S.D., Chandrasekar B., Murray D.R. et al.: Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000, 101: 2072-9. [Errata w: Circulation 2000, 102: 141].
43. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001, 38: 922-929.
44. Vyssoulis G.P., Marinakis A.G., Aznaouridis K.A. et al.: The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am. J. Hypertens. 2004, 17: 582-9.
45. Mallamaci F., Tripepi G., Maas R. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2004, 15: 435-441.
46. Feuerstein G.Z., Ruffolo R.R. Jr.: Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur. Heart J. 1996, 17(supl. B): 24-9.
47. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002, 53: 615-624.
48. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23: 615-621.
49. Ignarro L.J.: Experimental evidences of nitric oxide-dependent vasodilatatory activity of nebivolol, a third generation beta-blocker. Blood Pressure 2004, 13(S1): 3-17.
50. Cominacini L., Pasini A.F., Garbin U. et al.: Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. JACC 2003, 42: 1838-1844.
51. Arosio E., De Marchi S., Prior M. et al.: Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J. Hypertens. 2002, 30: 1793-1797.
52. Vittorio T.J., Lang C.C., Katz S.D. et al.: Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. Circulation 2003, 107: 290-293.
53. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000, 36: 3401-3403.
54. Kukin M.L., Kalman J., Charney R.H. et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99: 2645-51.
55. Nakamura K., Kusano K., Nakamura Y. et al.: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 105: 2867-71.
56. Lahiri A.: Neurohormonal mechanisms in congestive heart failure and the role of drugs with multiple actions: a review of carvedilol. Am. J. Therap. 1996, 3: 237-247.
57. Feuerstein G.Z., Yue T.L.: A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994, 48: 385-391.
58. Lopez B.L., Christopher T.A., Yue T.L. et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995, 51: 165-73.
59. De Grott A.A., Mathy M.J., van Zwieten P.A. et al.: Antioxidant activity of nebivolol in the rat aorta. J. Cardiovasc. Pharmacol. 2004, 43: 148-153.
60. Jacob S., Rett K., Henriksen E.J.: Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents. Am. J. Hypertens. 1998, 11: 1258-1265.
61. Van Os J.S., van Brummelen P., Woittiez A.J.J.: Betaxolol in obese hypertensive patients. Long term effects on blood pressure and serum lipids. Neth. J. Med. 1992, 40: 227-231.
62. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997, 314: 1512-1515.
63. He J., Ogden L.G., Bazzano L.A. et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiology follow-up study. Arch. Int. Med. 2001, 161: 996-1002.
64. Viscoli C.M., Horowitz R.I., Singer B.H.: Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann. Intern. Med. 1993, 118:99-105.
65. Pedersen T.R.: Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N. Engl. J. Med. 1985, 313: 1055-1058.
66. The Capricorn Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2002, 357: 1385-1390.
67. Aronow W.S., Ahn C., Kronzon I.: Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am. J. Cardiol. 2001, 88: 1298-1300.
68. Vantrimpont P., Rouleau J.L., Wun C.C. et al.: Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J. Am. Coll. Cardiol. 1997, 29: 229-236.
69. Swedberg K., Cleland J., Dargie H. et al, The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005, 26: 1115-1140.
70. Komajda M., Lutiger B., Madeira H. et al.: Tolerability of carvedilol and ACE-Inhibition in mild to heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN) Eur. J. Heart Fail. 2004, 6: 467-475.
71. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991, 325: 293-302.
72. Pfeffer M.A., Braunwald E., Moye L.A. et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992, 327: 669-77.
73. MERIT – HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomised Interventional Trial in Congestive Heart Failure (Merit–HF). Lancet 1999, 353: 2001-17.
74. CIBIS II Investigators and Committees: the Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet 1999, 353: 9-13.
75. Packer M., Coats A., Fowler M.B. et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001, 344: 1651-1658.
76. CIBIS investigators and committees: A randomized trial of betablockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994, 90: 1765-1773.
77. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112: 154-235.
78. Willenheimer R., van Veldhuisen D.J., Silke B. et al., CIBIS III Investigators: Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005, 112: 2426-2435.
79. Packer M., Bristow M.R., Cohn J.N. et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996, 334: 1349-1355.
80. The RESOLVD Investigators: Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation 2000, 101: 378-384.
81. Doughty R.N., Whalley G.A., Gamble G. et al., on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol. 1997, 29: 1060-1066.
82. Flather M.D., Shibata M.C., Coats A.J.S et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005, 26: 215-225.